| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 07/13/2005 | EP1552852A1 Inhibition of proliferation and infiltration of brain tumor cells caused by expression of ampa-type glutamate receptor subunit |
| 07/13/2005 | EP1552849A1 Immunotherapeutic for cancer |
| 07/13/2005 | EP1552845A1 Preventives/remedies for cancer |
| 07/13/2005 | EP1552842A1 Bicyclic pyrimidine derivatives |
| 07/13/2005 | EP1552841A1 Arsenic sulfide compounds and derivates thereof for the treatment of malignancies |
| 07/13/2005 | EP1552838A1 Rubrofusarin glycoside-containing composition |
| 07/13/2005 | EP1552827A1 Oral preventive/therapeutic agent for skin damage containing diacylglyceryl ether |
| 07/13/2005 | EP1552018A2 Methods and compositions relating to gene silencing |
| 07/13/2005 | EP1552002A2 Aptamer-toxin molecules and methods for using same |
| 07/13/2005 | EP1551998A2 Method for diagnosing non-small cell lung cancers |
| 07/13/2005 | EP1551990A2 Diagnosis and treatment of chemoresistant tumors |
| 07/13/2005 | EP1551972A2 Nucleic acids, polypeptides, single nucleotide polymorphisms and methods of use thereof |
| 07/13/2005 | EP1551962A2 Mitotic kinesin binding site |
| 07/13/2005 | EP1551877A2 Taci antibodies and uses thereof |
| 07/13/2005 | EP1551875A2 Buffered formulations for concentrating antibodies and methods of use thereof |
| 07/13/2005 | EP1551868A2 Factor involved in metastasis and uses thereof |
| 07/13/2005 | EP1551865A2 Hybrid molcules of macrolides with steroid/non-steroid anti-inflammatory, antineoplastic and antiviral active molecules |
| 07/13/2005 | EP1551853A1 Method for the separation of triglycoalkaloids |
| 07/13/2005 | EP1551850A1 2" oxo-voruscharin and derivatives thereof |
| 07/13/2005 | EP1551848A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors |
| 07/13/2005 | EP1551844A2 Antitumoral analogs of lamellarins |
| 07/13/2005 | EP1551841A1 Pyrazolopyrimidines as kinase inhibitors |
| 07/13/2005 | EP1551837A1 Phosphodiesterase 4 inhibitors |
| 07/13/2005 | EP1551824A1 Protein tyrosine kinase inhibitors |
| 07/13/2005 | EP1551822A2 Pentacyclic oxepines and derivatives thereof, process for their preparation and pharmaceutical compositions containing them |
| 07/13/2005 | EP1551812A2 Mitotic kinesin inhibitors |
| 07/13/2005 | EP1551795A1 Inhibitors of histone deacetylase |
| 07/13/2005 | EP1551461A2 Azo compounds for type i phototherapy |
| 07/13/2005 | EP1551452A1 Compositions and methods for therapeutic treatment |
| 07/13/2005 | EP1551448A2 Targeted cd1d molecules |
| 07/13/2005 | EP1551434A2 Identification of actinobacillus actinomycetemcomitans antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases |
| 07/13/2005 | EP1551425A2 Therapeutic formulations |
| 07/13/2005 | EP1551416A2 Method for treating erectile dysfunction and increasing libido in men |
| 07/13/2005 | EP1551412A1 Pharmaceutical compositions for the treatment of diseases related to neurotrophines |
| 07/13/2005 | EP1551409A1 Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability |
| 07/13/2005 | EP1551408A1 4-(4-methylpiperazin-1-ylmethyl)-n- 4-pyridin-3-yl)pyrimidin -2-ylamino)phenyl -benzamide for treating anaplastic thyroid cancer |
| 07/13/2005 | EP1551392A2 Novel lapacho compounds and methods of use thereof |
| 07/13/2005 | EP1551387A2 PKC ACTIVATION AS A MEANS FOR ENHANCING sAPPa SECRETION AND IMPROVING COGNITION USING BRYOSTATIN TYPE COMPOUNDS |
| 07/13/2005 | EP1551381A2 Styrylacrylonitrile compounds for inhibition of vascular endothelial growth factor |
| 07/13/2005 | EP1551378A2 Epo d + 5-fu/gemcitabine |
| 07/13/2005 | EP1551334A2 Medical device for intra-lumenal delivery of pharmaceutical agents |
| 07/13/2005 | EP1551330A1 Improvements in delivery technology |
| 07/13/2005 | EP1551228A2 Synthetic c-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases |
| 07/13/2005 | EP1551221A2 Nucleic acid compositions for stimulating immune responses |
| 07/13/2005 | EP1178969B1 Gastrin and cholecystokinin receptor ligands |
| 07/13/2005 | EP1161415B1 N-cyanomethylamides as protease inhibitors |
| 07/13/2005 | EP1113795B1 Tryptophanyl esters and their n-acyl derivatives for the prevention and treatment of diseases caused or exacerbated by oxidation processes |
| 07/13/2005 | EP1042291B1 Aryl-substituted pyridylalkane, alkene, and alkine carboxamides useful as cytostatic and immunosuppressive agents |
| 07/13/2005 | CN1639569A Methods and compositions for inducing an immune response |
| 07/13/2005 | CN1639317A Probiotic lactobacillus salivarius strains |
| 07/13/2005 | CN1639195A Selective targeting of tumor vasculature using antibody molecules |
| 07/13/2005 | CN1639194A Antibodies against cancer |
| 07/13/2005 | CN1639192A Anti-human tenascin monoclonal antibody |
| 07/13/2005 | CN1639191A 鼠李糖结合蛋白 Rhamnose-binding protein |
| 07/13/2005 | CN1639188A Hepta-, octa- and nonapeptides having antiangiogenic activity |
| 07/13/2005 | CN1639186A Inhibitors of kallikrein |
| 07/13/2005 | CN1639185A Cancer-associated epitope |
| 07/13/2005 | CN1639178A Novel, water-soluble porphyrin platinum compounds with high tumor selectivity and their use for the treatment of benign and malignant tumor diseases |
| 07/13/2005 | CN1639161A Alkyne-aryl phosphodiesterase-4 inhibitors |
| 07/13/2005 | CN1639159A N-aminoacetyl-pyrrolidine-2-carbonitriles and their use as DDP-IV inhibitors |
| 07/13/2005 | CN1639154A Pyranones useful as ATM inhibitors |
| 07/13/2005 | CN1639153A Indolylmaleimide derivatives |
| 07/13/2005 | CN1639151A Novel azepane derivatives |
| 07/13/2005 | CN1639150A 异喹啉衍生物 Isoquinoline derivatives |
| 07/13/2005 | CN1639149A Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth |
| 07/13/2005 | CN1639146A Fused tricyclic heterocycles useful for treating hyper-proliferative disorders |
| 07/13/2005 | CN1639145A Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative disorders |
| 07/13/2005 | CN1639139A 5-phenylthiazole derivatives and use as PI3 kinase inhibitors |
| 07/13/2005 | CN1639138A Biphenylmethyl-thiazolidinediones and analogues and their use as PPAR-gamma activators |
| 07/13/2005 | CN1639132A N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases |
| 07/13/2005 | CN1639130A Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same |
| 07/13/2005 | CN1639125A New inhibitors of histone deacetylase |
| 07/13/2005 | CN1639119A Substituted 2-amino-cycloalkanecarboxamides and their use as cysteine protease inhibitors |
| 07/13/2005 | CN1639115A Semicarbazide derivatives and their use as antithrombotics |
| 07/13/2005 | CN1638823A N-{5-[4-(4-methyl-piperazino-methyl)--benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine coated stents |
| 07/13/2005 | CN1638822A Compositions comprising undifferentiated fetal cells for the treatment of skin disorders |
| 07/13/2005 | CN1638807A Avidin dimers effective in increasing the concentration of radioactive biotin in pretargeted radioimmunotherapy |
| 07/13/2005 | CN1638805A Pharmaceutical formulation of IRESSA comprising a water-soluble cellulose derivative |
| 07/13/2005 | CN1638800A Human monoclonal antibodies against CD30 |
| 07/13/2005 | CN1638797A Cancer treatment |
| 07/13/2005 | CN1638796A Methods of administering anti-TNF alpha antibodies |
| 07/13/2005 | CN1638792A FGFR agonists |
| 07/13/2005 | CN1638780A Methods for particle-assisted polynucleotide immunization using a pulsed electric field |
| 07/13/2005 | CN1638778A Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer |
| 07/13/2005 | CN1638776A Substituted 3-aryl-5-aryl-[1, 2, 4]-oxadiazoles and analogs |
| 07/13/2005 | CN1638767A Combinations comprising epothilone derivatives and alkylating agent |
| 07/13/2005 | CN1638765A Mediators of Hedgehog signaling pathways, compositions and uses related thereto |
| 07/13/2005 | CN1638760A Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin |
| 07/13/2005 | CN1638757A 组织蛋白酶半胱氨酸蛋白酶抑制剂 Cathepsin cystatin |
| 07/13/2005 | CN1638753A Potentiation of therapeutic effects of fatty acids |
| 07/13/2005 | CN1638747A Sustained release pharmaceutical composition |
| 07/13/2005 | CN1638745A Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment |
| 07/13/2005 | CN1638739A Compound for treating assuetude disturbance |
| 07/13/2005 | CN1638734A Drug delivery system for the subconjunctival administration of fine grains |
| 07/13/2005 | CN1637020A Polyol-ifn-beta conjugates |
| 07/13/2005 | CN1637015A 17alpha-alkyl-17beta-oxy-estratrienes, uses thereof and pharmaceutical preparations |
| 07/13/2005 | CN1637013A Modified cpg oligodeoxynucleotide with improved immunoregulatory function |
| 07/13/2005 | CN1636992A Process for producing quinazoline ditosylate salt compounds |
| 07/13/2005 | CN1636991A Sodium-hydrogen exchanger type 1 inhibitor crystals |
| 07/13/2005 | CN1636983A Substituted heterocyclic compounds |